Can-Fite BioPharma Ltd. (CANF)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Can-Fite BioPharma Ltd. (CANF)
Company Performance

Current Price

as of Oct 15, 2024

$0.01

P/E Ratio

N/A

Market Cap

$16.86M

Description

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Metrics

Overview

  • HQRamat Gannull
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerCANF
  • Price$0.008278+7.37%

Trading Information

  • Market Cap$16.86M
  • Float99.98%
  • Average Daily Volume (1m)18,136,028
  • Average Daily Volume (3m)9,642,189
  • EPS-$0.02

Company

  • Revenue$2.74M
  • Rev Growth (1yr)0.69%
  • Net Income-$28.15M
  • Gross Margin97.98%
  • EBITDA Margin-1,100.94%
  • EBITDA-$30.17M
  • EV$2.53M
  • EV/Revenue0.92
  • P/EN/A
  • P/S14.46
  • P/B1.88
Documents
Factset Street Account
Can-Fite BioPharma reports 9M net income $0.0M vs year-ago ($0.0M) ($2.32, 0.00) (2023-11-30T12:06:29Z)
Can-Fite BioPharma receives FDA positive response to psoriasis pediatric plan with Piclidenoson ($2.03, 0.00) (2023-12-18T12:09:05Z)
Can-Fite Biopharma provides update on overall survival in patient with advanced liver cancer treated with namodenoson ($2.01, 0.00) (2023-11-21T12:12:24Z)
Can-Fite BioPharma halted; news pending ($2.60, +0.59) (2023-11-21T18:36:55Z)
Can-Fite BioPharma business update: All clinical programs and business development activities remain solidly on track ($2.03, 0.00) (2023-11-01T11:20:11Z)
Can-Fite BioPharma announces publication of data in Biomolecules supporting namodenoson - 6-K ($1.93, 0.00) (2023-10-30T11:13:56Z)
Can-Fite BioPharma announces exercise of warrants for approximately $3.0M in gross proceeds through H.C. Wainwright ($2.39, +0.39) (2023-11-21T19:22:29Z)